Skip to contentR
REGENXBIO Inc.
R
RGNXREGENXBIO Inc. Q2 2025 · 10-Q
Revenue$21.36M$21.36M−4.2% vs Q2 2024 Net Income-$70.87M-$70.87MN/M vs Q2 2024 EPS Diluted-$1.38-$1.38N/M vs Q2 2024 Operating Income-$63,278,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
REGENXBIO Inc. · CIK 1590877 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$49,733,000N/M Margins · derivedOperating margin-296.3%−44.9 pt vs Q2 2024
Net margin-331.8%−94.1 pt vs Q2 2024
ended Jun 30, 2025 · filed Aug 7, 2025 · 38 d after period end